Papadopoulos, Dimitrios
Mitsikostas, Dimos-Dimitrios D. http://orcid.org/0000-0002-4691-3388
Article History
First Online: 1 August 2018
Change Date: 20 December 2018
Change Type: Correction
Change Details: NEDA was evaluated as the proportion of patients free of relapses, 3-month confirmed disability progression, and free of new or newly enlarging T2 lesion and Gadolinium enhancing lesions.
Compliance with Ethical Standards
:
: No ethics approval or patient consent was obtained because all data used in this study were collected from previously published peer-reviewed articles.
: DP has received consulting, speaking fees, and travel grants from Bayer, Genesis Pharma, Merck, Novartis, Roche, Sanofi-Aventis, Specifar, and Teva. DDM has received consulting, speaking fees, and travel grants from Allergan, Amgen, Cefaly, ElectroCore, Genesis Pharma, Eli Lily, Merck-Serono, Novartis, Roche, Sanofi-Genzyme, Speficar, and Teva.
: No funding source had a role in the conception and preparation of this article.